Joseph V. Gulfo, MD, MBA, an alum and adjunct professor of Seton Hall University, manages the Cancer Biology blog. He obtained a BS degree in Biology from Seton Hall University in 1984, and was the Valedictorian of the School of Arts & Sciences. He obtained an MD degree from Rutgers New Jersey Medical School (formerly the University of Medicine and Dentistry of NJ) in 1984 and an MBA from Seton Hall University in 1995.

A serial entrepreneur, Dr. Gulfo is a leader in biopharma and medtech innovation and was responsible for the approval of a monoclonal antibody for prostate cancer (ProstaScint – Cytogen), a drug for bladder cancer (Valstar – Anthra Pharmaceuticals), and a medical device for melanoma detection (MelaFind – MELA Sciences).

Dr. Gulfo is the author of two books – The Care Quotient: Transforming Business Through People and  Innovation Breakdown: How the FDA and Wall Street Cripple Medical Advances. He spearheads the Initiative for Patient-Centered Innovation at Fairleigh Dickinson University and is a Visiting Scholar at the Mercatus Center of George Mason University. A contributor to The Hill and Inc.com, Dr. Gulfo is also on the faculty of the GLG Institute Master Class program and a member of the Life Sciences Council of Springboard Enterprises.

Twitter: @josephgulfo
LinkedIn: http://www.linkedin.com/in/josephgulfo